We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EL:EURONEXT PARISEssilorLuxottica SA Analysis

Data as of 2026-07-21 - not real-time

$82.35

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at $82.35, which sits below the 20‑day (82.23), 50‑day (83.64) and 200‑day (92.61) moving averages, signalling a short‑term bearish bias. RSI at 48.5 indicates a neutral momentum, while the MACD line crossing above its signal provides a modest bullish hint amid the downtrend. Volatility is elevated at over 33% on a 30‑day basis and beta exceeds 1.3, suggesting the share is more sensitive to market swings. Fundamental metrics show a negative profit margin (-1.7%), a high debt‑to‑equity ratio above 200%, and a dividend payout ratio well above 400%, all pointing to earnings and cash‑flow pressure. The discounted cash‑flow model values the company around $62, markedly below the current price, and the price‑to‑book multiple of 7.5 further underlines an overvalued posture.
Recent news cites the impact of geopolitical conflict and a proposed merger weighing on Q1 performance, adding a material downside catalyst. Despite a consensus “buy” rating and a forward EPS outlook of $3.18, the combination of technical weakness, leverage, and unsustainable dividend raises the near‑term risk profile, while the strong brand portfolio offers a potential upside if earnings recover over the longer horizon.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below all major moving averages indicating bearish momentum
  • Decreasing volume trend reducing liquidity support
  • Negative Q1 news impact from war and merger uncertainty

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Forward earnings estimate turning positive
  • Strong brand portfolio and revenue growth potential
  • Current overvaluation may correct toward DCF fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High gross margin and premium product positioning
  • Long‑term revenue growth and market share expansion opportunities
  • Potential deleveraging and dividend policy adjustment improving sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin-1.67%
P/E Ratio25.9
ROE-5.95%
ROA4.87%
Debt/Equity232.91
P/B Ratio7.5
Op. Cash Flow$1.8B
Free Cash Flow$1.8B

Technical Analysis

TrendBearish
RSI48.5
Support$76.83
Resistance$87.23
MA 20$82.23
MA 50$83.64
MA 200$92.61
MACDBullish
VolumeDecreasing
Fear & Greed Index91.23

Valuation

Fair Value$62.37
Target Price$95.15
Upside/Downside15.55%
GradeOvervalued
TypeValue
Dividend Yield1.67%

Risk Assessment

Beta1.42
Volatility33.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.